BTLA and neoplasm: Therapeutic strategies targeting BTLA to alleviate HVEM‐BTLA‐mediated suppression of T cell activity, such as the mAb Tifcemali125 and CAR‐T,126 are demonstrating significant potential in modulating anti‐tumour immunity.